Rhythm Pharmaceuticals
Price & Volume
Stats
See moreOpen | $81.28 |
Previous Close | $81.36 |
Day Range | $79.81-$83.56 |
52W Range | $55.31-$122.20 |
Market Cap | $5.6B |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $189.7M |
Revenue Growth (YoY) | 36.9% |
Gross Profit (12 Mos) | $170.2M |
Diluted EPS | -$3.11 |
News
See moreYahoo Finance • 4 days ago
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines
Yahoo Finance • 28 days ago
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Yahoo Finance • last month
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Yahoo Finance • last month
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
About
CEO | Dr. David P. Meeker M.D. |
CFO | Mr. Hunter C. Smith M.B.A. |
Address | 222 Berkeley Street, Boston, MA, United States, 02116 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 414 |